AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28712181 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 60
Study 28712181 — intervention group
Group type: COMPARATOR
Intervention: Extra virgin olive oil (EVOO) 2 tablespoons orally per day
Number of subjects: 60
Study 26495916 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐loading (400 ml Nutricia pre‐op®) 2 hours prior to surgery
Number of subjects: 40
Study 26495916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (clear water)
Number of subjects: 40
Study 23566997 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch® Verio™Pro+ BG meter
Number of subjects: 566
Study 22094481 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling (ASL) MRI
Number of subjects: 34
Study 22094481 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 34
Study 22094481 — intervention group
Group type: COMPARATOR
Intervention: ASL and FDG-PET
Number of subjects: 34
Study 19919976 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV320 10 mg
Number of subjects: 111
Study 19919976 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV320 15 mg
Number of subjects: 111
Study 19919976 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 111
Study 16798663 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 112
Study 16798663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Simvastatin + Celiprolol)
Number of subjects: 112
Study 16798663 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 112
Study 14747191 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding compounds
Number of subjects: 47
Study 14747191 — intervention group
Group type: COMPARATOR
Intervention: Carrier control
Number of subjects: 47
Study 11031342 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide antibiotic treatment (n = 11)
Number of subjects: 28
Study 11031342 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 7)
Number of subjects: 28
Study 11031342 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic subjects with M pneumoniae
Number of subjects: 28
Study 11031342 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 28
Study 9347661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane (CUP)
Number of subjects: 9
Study 9347661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose diacetate (CD)
Number of subjects: 9
Study 9347661 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone (PS)
Number of subjects: 9
Study 9347661 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (PAN)
Number of subjects: 9
Study 9347661 — intervention group
Group type: COMPARATOR
Intervention: Control (normal controls)
Number of subjects: 9
Study 9347661 — intervention group
Group type: COMPARATOR
Intervention: Predialysis ESRD patients
Number of subjects: 9
Study 8094995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 18
Study 8094995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3538922 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai Government Pharmaceutical Organization (GPO) antivenom
Number of subjects: 46
Study 3538922 — intervention group
Group type: EXPERIMENTAL
Intervention: Twyford Pharmaceutical antivenom
Number of subjects: 46
Study 3538922 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai Red Cross (TRC) antivenom
Number of subjects: 46
Study 3538922 — intervention group
Group type: COMPARATOR
Intervention: TRC antivenom
Number of subjects: 46
Study 3538922 — intervention group
Group type: COMPARATOR
Intervention: GPO antivenom
Number of subjects: 46
Study 3538922 — intervention group
Group type: COMPARATOR
Intervention: Twyford antivenom
Number of subjects: 46
Study 30086656 — intervention group
Group type: COMPARATOR
Intervention: Wealth group
Number of subjects: 0
Study 30086656 — intervention group
Group type: COMPARATOR
Intervention: Charity group
Number of subjects: 0
Study 30086656 — intervention group
Group type: EXPERIMENTAL
Intervention: Health group
Number of subjects: 0
Study 27231160 — intervention group
Group type: EXPERIMENTAL
Intervention: Stents-combination (Group I)
Number of subjects: 50
Study 27231160 — intervention group
Group type: COMPARATOR
Intervention: Stent-graft (Group II)
Number of subjects: 50
Study 24731537 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) tool assessments
Number of subjects: 380
Study 24731537 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improvements to the RoB tool
Number of subjects: 380
Study 22635965 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade autologous priming (AAP)
Number of subjects: 72
Study 22635965 — intervention group
Group type: COMPARATOR
Intervention: Control group (without AAP)
Number of subjects: 72
Study 20152214 — intervention group
Group type: EXPERIMENTAL
Intervention: New strategy combining clinical risk score and NT‐proBNP without exercise testing
Number of subjects: 320
Study 20152214 — intervention group
Group type: COMPARATOR
Intervention: Usual management involving exercise testing
Number of subjects: 320
Study 18662172 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin at 10 mg/kg every 24 h for 4 days
Number of subjects: 100
Study 18662172 — intervention group
Group type: COMPARATOR
Intervention: Standard of care therapy with vancomycin or semi-synthetic penicillin
Number of subjects: 100
Study 15920983 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAC Pinnacle system
Number of subjects: 14
Study 15920983 — intervention group
Group type: COMPARATOR
Intervention: Nomos Corvus system
Number of subjects: 14
Study 11830808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency probe at nonablative energy levels
Number of subjects: 39
Study 11830808 — intervention group
Group type: COMPARATOR
Intervention: Mechanical shaver
Number of subjects: 39
Study 10500534 — intervention group
Group type: EXPERIMENTAL
Intervention: University hospitals
Number of subjects: 1083
Study 10500534 — intervention group
Group type: COMPARATOR
Intervention: General hospitals
Number of subjects: 1083
Study 7568861 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg)
Number of subjects: 36
Study 7568861 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 36
Study 7568861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2209033 — intervention group
Group type: EXPERIMENTAL
Intervention: No weekly change (NWC)
Number of subjects: 112
Study 2209033 — intervention group
Group type: COMPARATOR
Intervention: Guidewire exchange (GWX)
Number of subjects: 112
Study 2209033 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous (PERC)
Number of subjects: 112
Study 398660 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 0
Study 398660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0
Study 398660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31865282 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp Cooling (SC)
Number of subjects: 51
Study 31132302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness module of dialectical behavioural therapy (DBT‐M)
Number of subjects: 65
Study 31132302 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal effectiveness module (DBT‐IE)
Number of subjects: 65
Study 28151944 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (20 participants)
Number of subjects: 40
Study 28151944 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (20 participants)
Number of subjects: 40
Study 25884980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri SBT2055 (LG2055) in fermented milk (FM)
Number of subjects: 0
Study 25884980 — intervention group
Group type: COMPARATOR
Intervention: Control group (FM without LG2055)
Number of subjects: 0
Study 23672520 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pelvic floor muscle training (PFMT)
Number of subjects: 100
Study 23672520 — intervention group
Group type: COMPARATOR
Intervention: Control group (written training instructions)
Number of subjects: 100
Study 23672520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 100
Study 21836158 — intervention group
Group type: EXPERIMENTAL
Intervention: Modal alerts
Number of subjects: 24
Study 21836158 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-modal alerts
Number of subjects: 24
Study 21836158 — intervention group
Group type: COMPARATOR
Intervention: No alert
Number of subjects: 24
Study 19423110 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 40
Study 19423110 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 17234318 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 12
Study 14998589 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 14998589 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (smoking cessation, exercise training, nutritional aspects, self-management programs)
Number of subjects: 0
Study 11429362 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection technique
Number of subjects: 50
Study 11429362 — intervention group
Group type: COMPARATOR
Intervention: Multiple injection technique
Number of subjects: 50
Study 9894701 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.02 mg/kg)
Number of subjects: 35
Study 9894701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9894701 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test
Number of subjects: 35
Study 9894701 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol test
Number of subjects: 35
Study 9894701 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive negative tilt test
Number of subjects: 35
Study 9894701 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative isoproterenol tilt test
Number of subjects: 35
Study 7994448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg oid
Number of subjects: 30
Study 7994448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2680083 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of phenylpropanolamine HCl (PPA)
Number of subjects: 102
Study 2680083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 5551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron 30 mg once daily
Number of subjects: 5
Study 5551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron 60 mg once daily
Number of subjects: 5
Study 5551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron 120 mg once daily
Number of subjects: 5
Study 5551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral iron 1 g followed by oral iron 60 mg
Number of subjects: 5
Study 5551272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 5551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstrable iron stores
Number of subjects: 5
Study 5551272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of demonstrable iron at 37th week
Number of subjects: 5
Study 31735256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-contrast training
Number of subjects: 19
Study 31735256 — intervention group
Group type: COMPARATOR
Intervention: Fixed-contrast training
Number of subjects: 19
Study 29677345 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-mg caffeine group
Number of subjects: 33
Study 29677345 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-mg caffeine group
Number of subjects: 33
Study 29677345 — intervention group
Group type: EXPERIMENTAL
Intervention: 180-mg caffeine group
Number of subjects: 33
Study 29677345 — intervention group
Group type: COMPARATOR
Intervention: 0-mg group (control)
Number of subjects: 33
Study 28643901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1000 mg iron)
Number of subjects: 110
Study 28643901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 26683949 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT + atorvastatin 20 mg daily + lansoprazole 30 mg daily (Group A)
Number of subjects: 104
Study 26683949 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT + atorvastatin 20 mg daily (Group B)
Number of subjects: 104
Study 26683949 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT + lansoprazole 30 mg daily (Group C)
Number of subjects: 104
Study 26683949 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 104
Study 26683949 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 104
Study 22750085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg
Number of subjects: 26
Study 22750085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20843556 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium (1‐1.2 mEq/L) + tamoxifen 80 mg/day
Number of subjects: 40
Study 20843556 — intervention group
Group type: COMPARATOR
Intervention: lithium (1‐1.2 mEq/L) + placebo
Number of subjects: 40
Study 18939399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tramadol (100 mg) and IV hyoscine N butylbromide (20 mg)
Number of subjects: 84
Study 18939399 — intervention group
Group type: COMPARATOR
Intervention: IV hyoscine N butylbromide (20 mg) only
Number of subjects: 84
Study 15825976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural characteristics identified through focus group discussions
Number of subjects: 26
Study 12538307 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural programme
Number of subjects: 316
Study 12538307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 316
Study 12538307 — intervention group
Group type: COMPARATOR
Intervention: High number of feeds (>11) in 24 hours
Number of subjects: 316
Study 10659801 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month aerobic training program
Number of subjects: 18
Study 8885906 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg) and medroxyprogesterone (10 mg) cyclically for 3 months
Number of subjects: 83
Study 8885906 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 83
Study 1520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily for 6 weeks
Number of subjects: 17
Study 1520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily for 6 weeks
Number of subjects: 17
Study 6500763 — intervention group
Group type: EXPERIMENTAL
Intervention: Isofezolac (50 mg) alone
Number of subjects: 6
Study 6500763 — intervention group
Group type: EXPERIMENTAL
Intervention: Isofezolac (50 mg) with aspirin (1 g)
Number of subjects: 6
Study 6500763 — intervention group
Group type: EXPERIMENTAL
Intervention: Isofezolac (50 mg) with phosphalugel (11 g aluminum phosphate)
Number of subjects: 6
Study 30895459 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension with prior climbing
Number of subjects: 20
Study 30895459 — intervention group
Group type: COMPARATOR
Intervention: Suspension without prior climbing
Number of subjects: 20
Study 30895459 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-suspension recovery
Number of subjects: 20
Study 30187789 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexima® Active O Convex
Number of subjects: 40
Study 26768572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola vaccine intervention
Number of subjects: 0
Study 26768572 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study 24798153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg/d
Number of subjects: 40
Study 24798153 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 40
Study 24798153 — intervention group
Group type: COMPARATOR
Intervention: Uric acid plus method (ascorbate oxidase assay)
Number of subjects: 40
Study 24798153 — intervention group
Group type: COMPARATOR
Intervention: Uric acid method (non‐ascorbate oxidase assay)
Number of subjects: 40
Study 22569288 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily atorvastatin (QD)
Number of subjects: 300
Study 22569288 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day atorvastatin (QOD)
Number of subjects: 300
Study 20437055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 45
Study 20437055 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 45
Study 20437055 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 45
Study 17509688 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15%
Number of subjects: 163
Study 17509688 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide 1%
Number of subjects: 163
Study 17224714 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 9
Study 12910715 — intervention group
Group type: EXPERIMENTAL
Intervention: KC-404 sustained release tablets (20 mg)
Number of subjects: 19
Study 12910715 — intervention group
Group type: COMPARATOR
Intervention: KC-404 capsules (20 mg)
Number of subjects: 19
Study 10839227 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) performing 36 maximal isokinetic eccentric contractions of the elbow flexors (ECC1) followed by a repeated bout (ECC2) two days later
Number of subjects: 20
Study 10839227 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) performing 36 maximal isokinetic eccentric contractions of the elbow flexors (ECC1)
Number of subjects: 20
Study 9352730 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori seropositive children (n=87)
Number of subjects: 157
Study 9352730 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control group (n=50)
Number of subjects: 157
Study 9352730 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive children with recent upper gastrointestinal bleeding (n=8)
Number of subjects: 157
Study 9352730 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric data from institutionalised children
Number of subjects: 157
Study 8254651 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI cluster group membership
Number of subjects: 517
Study 3924221 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (postural drainage, external help with breathing, percussion, and vibration)
Number of subjects: 171
Study 3924221 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 171
Study 3924221 — intervention group
Group type: COMPARATOR
Intervention: Control (advice on expectoration, deep breathing, and how to exercise to avoid thrombosis)
Number of subjects: 171
Study 30627850 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE + Corrections (computerized counseling session plus post‐incarceration text messaging intervention)
Number of subjects: 110
Study 30627850 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 110
Study 28816883 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg IV atropine
Number of subjects: 41
Study 28816883 — intervention group
Group type: COMPARATOR
Intervention: No atropine
Number of subjects: 41
Study 28816883 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic desaturation
Number of subjects: 41
Study 26132827 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body mass)
Number of subjects: 28
Study 26132827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26132827 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 28
Study 25041870 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 504
Study 25041870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 22595327 — intervention group
Group type: EXPERIMENTAL
Intervention: McDavid 199 Lightweight ankle brace
Number of subjects: 20
Study 22595327 — intervention group
Group type: COMPARATOR
Intervention: No ankle brace
Number of subjects: 20
Study 19948946 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 400 mg nilotinib
Number of subjects: 21
Study 19948946 — intervention group
Group type: COMPARATOR
Intervention: Water with 400 mg nilotinib
Number of subjects: 21
Study 18603410 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression with ice (Group A)
Number of subjects: 95
Study 18603410 — intervention group
Group type: COMPARATOR
Intervention: Compression without ice (Group B)
Number of subjects: 95
Study 18603410 — intervention group
Group type: COMPARATOR
Intervention: No compression (Group C)
Number of subjects: 95
Study 15819283 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib, 30 mg once daily
Number of subjects: 528
Study 15819283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 800 mg 3 times daily
Number of subjects: 528
Study 15819283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 12729814 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vehicle phone distraction task
Number of subjects: 42
Study 12729814 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no phone distraction)
Number of subjects: 42
Study 10589361 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept-MTX
Number of subjects: 0
Study 10589361 — intervention group
Group type: COMPARATOR
Intervention: Placebo-MTX
Number of subjects: 0
Study 8699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape
Number of subjects: 150
Study 8699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional booklet
Number of subjects: 150
Study 8699272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture
Number of subjects: 150
Study 1862063 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration chart
Number of subjects: 30
Study 1862063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chart)
Number of subjects: 30
Study 6419596 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (6 mg per day)
Number of subjects: 40
Study 6419596 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (500 mg per day)
Number of subjects: 40